

# NEW ZEALAND DATA SHEET

## WARNINGS

### Limitations of use

Because of the risks associated with the use of opioids, morphine should only be used in patients for whom other treatment options, including non-opioid analgesics, are ineffective, not tolerated or otherwise inadequate to provide appropriate management of pain (see **section 4.4 Special warnings and precautions for use**).

### Hazardous and harmful use

Morphine poses risks of hazardous and harmful use which can lead to overdose and death. Assess the patient's risk of hazardous and harmful use before prescribing and monitor the patient regularly during treatment (see **section 4.4 Special warnings and precautions for use**).

### Life-threatening respiratory depression

Serious, life-threatening or fatal respiratory depression may occur with the use of morphine. Be aware of situations which increase the risk of respiratory depression, modify dosing in patients at risk and monitor patients closely, especially on initiation or following a dose increase (see **section 4.4 Special warnings and precautions for use**).

### Concomitant use of benzodiazepines and other central nervous system (CNS) depressants, including alcohol

Concomitant use of opioids with other opioid analgesics, benzodiazepines, gabapentinoids, cannabis, sedatives, hypnotics, tricyclic antidepressants, antipsychotics, antihistamines, centrally-active anti-emetics, general anaesthetics, tranquilisers, beta blockers, or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Limit dosages and durations to the minimum required and monitor patients for signs and symptoms of respiratory depression and sedation. Caution patients not to drink alcohol while using morphine (see **section 4.4 Special warnings and precautions for use**).

## 1. PRODUCT NAME

DBL™ Morphine Sulfate Injection, 5 mg/mL, solution for injection

DBL™ Morphine Sulfate Injection, 10 mg/mL, solution for injection

DBL™ Morphine Sulfate Injection, 15 mg/mL, solution for injection

DBL™ Morphine Sulfate Injection, 30 mg/mL, solution for injection

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each mL of DBL Morphine Sulfate Injection contains 5, 10, 15, or 30 mg of morphine sulfate pentahydrate. All four strengths are isotonic preparations.

For the full list of excipients, see **section 6.1 List of excipients**.

## 3. PHARMACEUTICAL FORM

Solution for injection.

DBL Morphine Sulfate Injection is a clear colourless to slightly yellow, sterile solution.

The pH of the solution ranges from 3.2 to 4.0.

## 4. CLINICAL PARTICULARS

### 4.1 Therapeutic indications

DBL Morphine Sulfate Injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

DBL Morphine Sulfate Injection may also be used as a pre-operative medication and as an analgesic adjunct in general anaesthesia.

### 4.2 Dose and method of administration

#### Dose

DBL Morphine Sulfate Injection may be given by the subcutaneous, intramuscular or intravenous route. The subcutaneous route is not suitable for oedematous patients. Note: Opioid antagonists and facilities for administration of oxygen and control of respiration should be available during, and immediately following parenteral administration.

#### *Subcutaneous, Intramuscular and Slow Intravenous Administration*

**Adults:** DBL Morphine Sulfate Injection is usually administered by intramuscular or subcutaneous injection, in the range of 5 to 20 mg, depending on the cause of pain and the patient response. Doses may be repeated every 4 to 6 hours.

DBL Morphine Sulfate Injection may also be given intravenously when a rapid onset of action is desired. The dose is usually in the range of 2.5 to 15 mg diluted in 4 to 5 mL of Water for Injections given slowly over 4 to 5 minutes.

**Children:** DBL Morphine Sulfate Injection is given by intramuscular or subcutaneous injection in doses of 0.1 to 0.2 mg/kg bodyweight to a maximum of 15 mg. Injection may be repeated every 4 to 6 hours.

When a rapid onset of action is desirable, in a closely monitored environment, morphine may be titrated intravenously with caution, in a dose of 0.05 to 0.1 mg/kg, incrementally over 5 to

15 minutes. Repeat intravenous dosing is unsubstantiated as a method of analgesic therapy in children.

DBL Morphine Sulfate Injection is not usually given pre-operatively in children under 1 year, and it should be given with extreme care to neonates. It should not be given to premature infants (see **section 4.3 Contraindications**).

### ***Continuous Intravenous Infusion***

The dosage of morphine should be titrated according to the patient's analgesic requirements and previous opiate experience. For the management of acute pain via intravenous infusion, most adults with no previous history of opioid intake can be continued on 0.5 to 2.0 mg/hour after adequate analgesic therapy has been established.

In children, an infusion dose of 0.01 to 0.05 mg/kg/hour morphine to a maximum intravenous dose of 4 mg/hour is recommended.

### ***Patient-Controlled Analgesic Therapy (PCA)***

PCA allows patients to assess their own level of pain and consequently titrate the amount of morphine they require for adequate pain control against sedation and other side effects.

The dosages and time intervals are preset into a microprocessor-controlled infusion pump. When the patient experiences pain, a button is depressed by the patient and a dose of morphine is administered intravenously. If the patient should depress the button before the preset time interval (lockout interval) has elapsed, no extra drug is administered.

For adults, demand doses of 0.5 to a maximum of 1.5 mg morphine have been given via PCA using a lockout interval of 6 to 10 minutes. Along with the self-administered dose of morphine, some syringe pumps also deliver a background continuous infusion of morphine at a basal rate. If a background infusion is adopted, a dose of 1 mg/hour morphine is often used in adults. Some PCA pumps allow a maximum dosage over a defined period to be preset in order to avoid patient overdosage.

There is limited clinical experience of the use of PCA in children. However, a demand dose of 0.01 to 0.025 mg/kg morphine has been used successfully in children and adolescents between the ages of 7 and 19 years with a lockout interval of 6 to 10 minutes. If a background infusion is employed, an infusion dose of 0.015 mg/kg/hour morphine may be used in children.

The demand dosage and lockout interval should be determined according to the patient's analgesic requirements. Patients receiving a background infusion of morphine should generally receive a smaller demand dose relative to equivalent patients utilising a demand dose only.

Techniques such as PCA with background continuous infusion are associated with a higher rate of adverse effects and require close monitoring.

### **General Information for Cancer Pain**

When morphine is administered by continuous intravenous or subcutaneous infusion for relief of severe, chronic pain associated with cancer, the dosage of morphine must be individualised according to the response and tolerance of the patient. In some patients with exceptionally severe, chronic pain it may be necessary to exceed the usual dosage. Reduced dosage is

indicated in poor-risk patients, in very young or very old patients, and in patients receiving other CNS depressants.

Orally administered morphine should be used in preference to parenteral morphine whenever adequate pain control can be achieved by this route. However, oral morphine is often inadequate or impractical in the terminally ill patient.

Patients being converted from oral morphine to either intramuscular (IM), intravenous (IV) or subcutaneous (SC) morphine require dosage reduction (about one-sixth), since about 60% of oral morphine is metabolised in first-pass metabolism (i.e. 1 mg of either IM, SC or IV morphine for every 6 mg of oral morphine). The dose should then be titrated according to the patient's clinical response.

For cancer pain, DBL Morphine Sulfate Injection should be given regularly around the clock, in most instances every 4 hours. The basis of pain control with DBL Morphine Sulfate Injection should be regular scheduling rather than on an 'as required' or PRN narcotic order. Patients requiring high doses of morphine usually need to be awakened for medication during the night to prevent morning pain.

### **Morphine Dosage Increases**

Dosage increases for intravenous, subcutaneous or intramuscular administration of morphine should not be made more frequently than every 24 hours, since it will take approximately 4 to 5 morphine half-lives to attain a new steady state concentration in a patient with normal liver and kidney function.

Following all dosage increases, the patient must be monitored closely for side effects, the most common being sedation, nausea, vomiting, constipation and hypotension.

### **Treatment Goals and Discontinuation**

Before initiating treatment with morphine, a treatment strategy including treatment duration and treatment goals, and a plan for end of the treatment, should be agreed together with the patient, in accordance with pain management guidelines. During treatment, there should be frequent contact between the physician and the patient to evaluate the need for continued treatment, consider discontinuation and to adjust dosages if needed.

When a patient no longer requires therapy with morphine, it may be advisable to taper the dose gradually to prevent symptoms of withdrawal. In absence of adequate pain control, the possibility of hyperaesthesia, drug tolerance and progression of underlying disease should be considered (see **section 4.4 Special warnings and precautions for use**).

### **Duration of treatment**

Morphine should not be used longer than necessary.

**Warning:** As with all parenteral drug products, intravenous admixtures should be visually inspected for clarity, particulate matter, precipitate and leakage prior to administration, whenever solution and container permit. Solutions showing haziness, particulate matter, precipitate or leakage should not be used. Development of a yellow colour in morphine solutions does not indicate toxicity or loss of potency or efficacy.

### 4.3 Contraindications

DBL Morphine Sulfate Injection is contraindicated in the following situations:

- patients with known hypersensitivity to morphine or other opioids;
- patients with severe respiratory disorder, acute respiratory disorder, respiratory depression or failure, especially in the presence of cyanosis and/or increased bronchial secretion;
- patients with asthma or other obstructive airways disorder;
- other conditions where respiratory reserve is depleted, such as emphysema, chronic bronchitis or kyphoscoliosis;
- cor pulmonale;
- severe depressed level of consciousness;
- diabetic ketoacidosis where there is a danger of coma;
- severe liver disorder or incipient hepatic encephalopathy;
- following biliary tract surgery or surgical anastomosis;
- biliary pain;
- gastrointestinal obstruction;
- paralytic ileus;
- suspected surgical abdomen;
- acute diarrhoeal conditions associated with antibiotic-induced pseudomembranous colitis;
- diarrhoea caused by poisoning (until the toxic material has been eliminated);
- in patients who are taking or who have taken monoamine oxidase inhibitors (MAOIs) within the previous fourteen days;
- phaeochromocytoma (due to risk of pressor response to histamine release);
- arrhythmia;
- cardiac failure secondary to lung disorder;
- alcoholism or delirium tremens;
- comatose patients;
- head injury;
- brain tumour;
- increased intracranial or cerebrospinal pressure and in convulsive states such as status epilepticus, tetanus or strychnine poisoning (see **section 4.4 Special warnings and precautions for use**).

Morphine is contraindicated in premature infants or during labour for delivery of premature infants.

The administration of morphine via PCA to children less than six years of age and adults with poor cognitive function is contraindicated.

The continuous intravenous infusion of morphine in patients with liver disorder or nephropathy is contraindicated (see **section 4.4 Special warnings and precautions for use**).

## **4.4 Special warnings and precautions for use**

Therapy should only be initiated by a specialist with experience in chronic pain management and in accordance with guidelines approved by the New Zealand Medical Association.

### **Hazardous and Harmful Use**

DBL Morphine Sulfate Injection is an opioid and a potential drug of abuse, misuse and dependence. Dependence can occur in patients appropriately prescribed morphine at recommended doses.

The risk of dependence is increased in patients with a personal or family history of substance abuse (including alcohol and prescription and illicit drugs), in current tobacco users or in patients with a personal history of mental illness. The risk also increases the longer the drug is used and with higher doses. Patients should be assessed for their risks for drug abuse or dependence prior to being prescribed morphine.

All patients receiving opioids should be routinely monitored for signs of misuse and abuse. Opioids are sought by people with addiction and may be subject to diversion. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on the safe storage and proper disposal of any unused drug (see **section 6.6 Special precautions for disposal**). Caution patients that abuse of oral or transdermal forms of opioids by parenteral administration can result in serious adverse events, which may be fatal.

Patients should be advised not to share morphine with anyone.

### **Accidental Ingestion/Exposure**

Accidental ingestion or exposure of morphine, especially by children, can result in a fatal overdose of morphine. Patients and their caregivers should be given information on safe storage and disposal of unused morphine (see **section 6.6 Special precautions for disposal**).

### **Respiratory Depression**

Serious, life-threatening or fatal respiratory depression can occur with the use of opioids even when used as recommended. It can occur at any time during the use of morphine, but the risk is greatest during initiation of therapy or following an increase in dose. Patients should be monitored closely for respiratory depression at these times.

The risk of life-threatening respiratory depression is also higher in elderly, frail, or debilitated patients, in patients with existing impairment of respiratory function, in those suffering from conditions accompanied by hypoxia or hypercapnia (e.g., chronic obstructive pulmonary disease, asthma), when even moderate therapeutic doses may significantly decrease pulmonary ventilation and in patients with abnormal hepatic function and renal impairment. Morphine should therefore be used only in patients for whom its use is judged to be essential, with extreme caution and close monitoring (see **section 4.2 Dose and method of administration**). The use of opioids is contraindicated in patients with severe respiratory disease, acute respiratory disorder and respiratory depression (see **section 4.3 Contraindications**).

The respiratory depressant effects of morphine and its capacity to increase cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a pre-existing increase in intracranial pressure. Furthermore, opioids produce adverse reactions, including confusional state, miosis and vomiting, which may obscure the clinical course of patients with head injuries.

Large doses and/or rapid administration of morphine may produce rapid onset of respiratory depression including central sleep apnoea syndrome and sleep-related hypoxia, bradycardia, or even cardiac arrest.

The risk of respiratory depression is greater with the use of high doses of opioids and in opioid naive patients. Initiation of opioid treatment should be at the lower end of the dosage recommendations with careful titration of doses to achieve effective pain relief. Careful calculation of equianalgesic doses is required when changing opioids together with consideration of pharmacological differences between opioids. Consider starting the new opioid at a reduced dose to account for individual variation in response (see **section 4.2 Dose and method of administration**).

Resuscitative equipment and opioid antagonist must be readily available.

### **Seizures**

Morphine may aggravate pre-existing seizure conditions. If dosage is escalated substantially above recommended levels because of drug tolerance development, seizures may occur in individuals without a history of seizures.

### **Serotonin Syndrome (SS)**

The development of serotonin syndrome (SS), which is potentially life-threatening, has been reported with opioid use, including with morphine. These reports generally occurred when morphine was used concomitantly with serotonergic drugs (see **section 4.5 Interactions with other medicines and other forms of interaction**). Signs of SS may include clonus, agitation, hyperhidrosis, tremor, hyperreflexia, hypertonia and increased body temperature.

### **Cardiovascular Instability**

While low doses of intravenously administered morphine have little effect on cardiovascular stability, high doses are excitatory, resulting from sympathetic hyperactivity and increase in circulatory catecholamines. Have naloxone injection and resuscitative equipment immediately available for use in case of life-threatening or intolerable side effects and whenever morphine therapy is being initiated.

### **Supraventricular Tachycardias**

Because of possible vagolytic action that may produce a significant increase in the ventricular response rate, morphine should be used with caution in patients with atrial flutter and other supraventricular tachycardias.

### **Hypotensive Effect**

The administration of morphine may result in severe hypotension in the post-operative patient or any individual whose ability to maintain blood pressure has been compromised by a depleted

blood volume, shock, or the administration of such drugs as phenothiazines or certain anaesthetics.

Morphine may produce orthostatic hypotension in ambulatory patients.

### **Shock Patients**

In patients with shock, impaired perfusion may prevent complete absorption following subcutaneous or intramuscular injection of morphine. Repeated administration may result in overdose due to an excessive amount of morphine suddenly being absorbed when circulation is restored.

### **Drug tolerance, Drug Use Disorder (Abuse and Dependence) and Withdrawal**

Neuroadaptation of the opioid receptors to repeated administration of opioids can produce drug tolerance and physical dependence. Drug tolerance is the need for increasing doses to maintain analgesic therapy. Drug tolerance may occur to both the desired and undesired effects of the opioid. Psychological dependence, physical dependence, and drug tolerance may develop upon repeated administration of morphine. However, it should be noted that clinically significant respiratory depression, dependence, rapid drug tolerance and euphoric mood rarely develop when doses of morphine are carefully titrated against the pain in patients with terminal disease and severe pain.

Repeated use of morphine can lead to Drug Use Disorder (DUD). A higher dose and longer duration of opioid treatment can increase the risk of developing DUD. Abuse or intentional misuse of morphine may result in overdose and/or death.

The risk of developing DUD is increased in patients with a personal or a family history (parents or siblings) of substance use disorders (including alcohol use disorder), in current tobacco users or in patients with a personal history of other mental health disorders (e.g., major depression, anxiety and personality disorders).

Before initiating treatment with morphine and during the treatment, treatment goals and a discontinuation plan should be agreed with the patient (see **section 4.2 Dose and method of administration**). Before and during treatment the patient should also be informed about the risks and signs of DUD. If these signs occur, patients should be advised to contact their physician.

Patients will require monitoring for signs of drug-seeking behaviour (e.g., too early requests for refills). This includes the review of concomitant opioids and psycho-active drugs (like benzodiazepines). For patients with signs and symptoms of DUD, consultation with an addiction specialist should be considered.

Drug dependence does not develop if morphine is administered regularly at individually optimised doses to the cancer patient with moderate to severe pain. While a certain degree of physical dependence occurs, a psychological dependence does not occur. If a cancer patient no longer requires an opioid for pain control, a gradual reduction in dose will prevent withdrawal syndrome, although the symptoms are usually mild or absent even after abrupt discontinuance. Clinically significant drug tolerance to morphine is unusual in the cancer patient being treated for severe pain. In most cases, a plateauing of dose requirements is seen, as a need to increase morphine dose means an increase in pain and not drug tolerance.

Physical dependence, which can occur after several days to weeks of continued opioid usage, results in withdrawal syndrome if the opioid is ceased abruptly or the dose is significantly reduced. Withdrawal syndrome can also occur following the administration of an opioid antagonist (e.g., naloxone) or partial agonist (e.g., buprenorphine). Withdrawal syndrome can result in some or all of the following symptoms: dysphoria, restlessness, increased lacrimation, rhinorrhoea, yawning, hyperhidrosis, chills, myalgia, mydriasis, palpitations, irritability, agitation, anxiety, hyperkinesia, tremor, pain, back pain, arthralgia, asthenia, abdominal pain, insomnia, nausea, decreased appetite, vomiting, diarrhoea, hypertension, increased respiratory rate, tachycardia, piloerection, sneezing, seizures, and pyrexia.

When discontinuing morphine in a person who may be physically dependent, the drug should not be ceased abruptly but withdrawn by tapering the dose gradually (see **Ceasing Opioids** and **section 4.2 Dose and method of administration**).

### **Ceasing Opioids**

Abrupt discontinuation or rapid decreasing of the dose in a person physically dependent on an opioid may result in serious withdrawal syndrome and uncontrolled pain (see **Drug Tolerance, Drug Use Disorder (Abuse and Dependence) and Withdrawal**). Such symptoms may lead the patient to seek other sources of licit or illicit opioids. Opioids should not be ceased abruptly in a patient who is physically dependent but withdrawn by tapering the dose slowly. Factors to take into account when deciding how to discontinue or decrease therapy include the dose and duration of the opioid the patient has been using, the type of pain being treated and the physical and psychological attributes of the patient.

A multimodal approach to pain management should be in place before initiating an opioid analgesic therapy taper. During tapering, patients require regular review and support to manage any increase in pain, psychological distress and withdrawal syndrome.

There are no standard tapering schedules suitable for all patients and an individualised plan is necessary. In general, tapering should involve a dose reduction of no more than 10% to 25% every 2 to 4 weeks (see **section 4.2 Dose and method of administration**). If the patient is experiencing increased pain or serious withdrawal syndrome, it may be necessary to go back to the previous dose until stable before proceeding with a more gradual taper.

When ceasing opioids in a patient who has a suspected drug use disorder, the need for medication assisted treatment and/or referral to a specialist should be considered.

### **Neonatal Drug Withdrawal Syndrome**

Refer to **section 4.6 Fertility, pregnancy and lactation – Use in Pregnancy – Category C**.

### **Use of Opioids in Chronic (Long-term) Non-cancer Pain (CNCP)**

Opioid analgesics have an established role in the treatment of acute pain, cancer pain and palliative and end-of-life care. Current evidence does not generally support opioid analgesics in improving pain and function for most patients with chronic non-cancer pain. The development of drug tolerance and physical dependence and risks of adverse effects, including hazardous and harmful use, increase with the length of time a patient takes an opioid. The use of opioids for long-term treatment of CNCP is not recommended.

The use of an opioid to treat CNCP should only be considered after maximised non-pharmacological and non-opioid treatments have been tried and found ineffective, not tolerated or otherwise inadequate to provide sufficient management of pain. Opioids should only be prescribed as a component of comprehensive multidisciplinary and multimodal pain management.

Opioid therapy for CNCP should be initiated as a trial in accordance with clinical guidelines and after a comprehensive biopsychosocial assessment has established a cause for the pain and the appropriateness of opioid therapy for the patient (see **Hazardous and Harmful Use**). The expected outcome of therapy (pain reduction rather than complete abolition of pain, improved function and quality of life) should be discussed with the patient before commencing opioid treatment, with agreement to discontinue treatment if these objectives are not met.

Owing to the varied response to opioids between individuals, it is recommended that all patients be started at the lowest appropriate dose and titrated to achieve an adequate level of analgesic therapy and functional improvement with minimum adverse reactions. Immediate-release products should not be used to treat chronic pain but may be used for a short period in opioid-naïve patients to develop a level of drug tolerance before switching to a modified-release formulation. Careful and regular assessment and monitoring is required to establish the clinical need for ongoing treatment. Discontinue opioid therapy if there is no improvement of pain and/or function during the trial period or if there is any evidence of misuse or abuse. Treatment should only continue if the trial has demonstrated that the pain is opioid-responsive and there has been functional improvement. The patient's condition should be reviewed regularly, and the dose tapered off slowly if opioid treatment is no longer appropriate (see **Ceasing Opioids**).

### **Hyperaesthesia**

Hyperaesthesia may occur with the use of opioids, particularly at high doses. Hyperaesthesia may manifest as an unexplained increase in pain, increased levels of pain with increasing opioid dosages or diffuse sensitivity not associated with the original pain. Hyperaesthesia should not be confused with drug tolerance (see **Drug tolerance, Drug Use Disorder (Abuse and Dependence) and Withdrawal**). If opioid-induced hyperaesthesia is suspected, the dose should be reduced and tapered off if possible. A change to a different opioid may be required.

### **Adrenal Insufficiency**

Cases of reversible adrenal insufficiency requiring monitoring and glucocorticoid replacement therapy have been reported with opioid use. Presentation of adrenal insufficiency may include non-specific symptoms and signs including nausea, vomiting, decreased appetite, fatigue, asthenia, dizziness, and hypotension.

### **Impaired Gastric Emptying**

Morphine impairs gastric emptying, which may be expected to increase the risks of aspiration, either associated with morphine-induced CNS depression or coma, or during or after general anaesthesia.

### **Acute Abdominal Conditions**

The administration of morphine or other opioids may obscure the diagnosis or clinical course in patients with acute abdominal conditions. Morphine should be used with caution in patients

with inflammatory or obstructive bowel disorders, or with ulcerative colitis, and should only be used when necessary in patients with acute pancreatitis.

### **Hepatobiliary Disorders**

Morphine should either be avoided in patients with hepatobiliary tract disorders or they should be given with an antispasmodic. Morphine may cause dysfunction and spasm of the sphincter of Oddi, thus raising intrabiliary pressure and increasing the risk of biliary tract disorders and pancreatitis. Therefore, in patients with biliary tract disorders, morphine may exacerbate pain (use in biliary colic is contraindicated, see **section 4.3 Contraindications**). In patients given morphine after cholecystectomy, biliary pain has been induced.

### **Sickle Cell Disease (SCD) and Acute Chest Syndrome (ACS)**

Due to a possible association between ACS and morphine use in SCD patients treated with morphine during sickle cell anaemia with crisis, close monitoring for ACS symptoms is warranted.

### **Decreased Sex Hormones and Increased Blood Prolactin**

Long-term use of opioid analgesic therapy may be associated with decreased sex hormone levels and increased blood prolactin. Symptoms include decreased libido, erectile dysfunction or amenorrhoea.

### **Other Special Risk Patients**

Morphine should be given with caution, and in reduced dosages, to certain patients, such as the elderly or debilitated and those with severe abnormal hepatic function or renal impairment, hypothyroidism, Addison's disease, myxoedema, and benign prostatic hyperplasia or urethral stenosis. Caution should also be observed if morphine is administered to patients with psychotic disorder or myasthenia gravis. Morphine should be used with extreme caution in patients with disorders characterised by hypoxia, since even usual therapeutic doses of opioids may decrease respiratory drive to the point of apnoea while simultaneously increasing airway resistance.

### **Risks from Concomitant Use of Benzodiazepines or Other CNS Depressants, including Alcohol**

Concomitant use of opioids and benzodiazepines or other CNS depressants, including alcohol, may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing of morphine with CNS depressant medicines, such as other opioid analgesics, benzodiazepines, gabapentinoids, cannabis, sedatives, hypnotics, tricyclic antidepressants, antipsychotics, antihistamines, centrally-active anti-emetics, general anaesthetics, tranquilisers, beta blockers or other CNS depressants should be reserved for patients for whom other treatment options are not possible.

If a decision is made to prescribe morphine concomitantly with any of the medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible. In patients already receiving an opioid analgesic, prescribe a lower initial dose of the benzodiazepine or other CNS depressant than indicated in the absence of an opioid, and titrate based on clinical response. If an opioid analgesic is initiated in a patient already taking a

benzodiazepine or other CNS depressant, prescribe a lower initial dose of the opioid analgesic, and titrate based on clinical response.

Patients should be followed closely for signs and symptoms of respiratory depression and sedation. Patients and their caregivers should be made aware of these symptoms. Patients and their caregivers should also be informed of the potential harms of consuming alcohol while using morphine.

Morphine may cause somnolence and may impair the mental and/or physical abilities needed to perform potentially hazardous tasks, such as driving a car or operating machinery. Advise patients not to drive or operate heavy machinery until the effects of concomitant use of the benzodiazepine or other CNS depressant have been determined.

Screen patients for risk of substance use disorders, including drug abuse and misuse, and warn them of the risk for overdose and death associated with the use of concomitant CNS depressants including alcohol and illicit drugs (see **section 4.5 Interactions with other medicines and other forms of interaction**). If respiratory depression of any form occurs, consider decreasing the opioid dosage using best practices for opioid taper.

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of medicine-related mortality compared to use of opioid analgesics alone. Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid analgesics (see **section 4.5 Interactions with other medicines and other forms of interaction**).

### **Oral P2Y<sub>12</sub> Inhibitor Antiplatelet Therapy**

Within the first day of concomitant P2Y<sub>12</sub> inhibitor and morphine treatment, reduced efficacy of P2Y<sub>12</sub> inhibitor treatment has been observed (see **section 4.5 Interactions with other medicines and other forms of interactions**).

### **Severe Cutaneous Adverse Reactions (SCARs)**

Acute generalised exanthematous pustulosis (AGEP), which can be life-threatening or fatal, has been reported in association with morphine treatment. Most of these reactions occurred within the first 10 days of treatment. Patients should be informed about the signs and symptoms of AGEP and advised to seek medical care if they experience such symptoms.

If signs and symptoms suggestive of these skin reactions appear, morphine should be withdrawn and an alternative treatment considered.

### **Renal Impairment or Abnormal Hepatic Function**

Morphine may have a prolonged duration and cumulative effect in patients with renal impairment or abnormal hepatic function. In these patients, analgesic therapy may last for 6, 8 or even up to 24 hours following a standard dose. Continuous infusions are contraindicated in these patients (see **section 4.3 Contraindications**).

Caution should be observed when morphine is administered to patients with renal impairment, as the pharmacologically active metabolite, morphine-6-glucuronide, may accumulate in these patients. This may lead to CNS and respiratory depression.

## Paediatric Use

Safety and efficacy of morphine in neonates have not been established. However, neonates have an enhanced susceptibility to the respiratory depressant effects of morphine. Morphine should not be administered to premature infants (see **section 4.3 Contraindications**).

Morphine should not be administered via PCA to children less than six years of age with poor cognitive function.

## Elderly Patients

See **Other Special Risk Patients and Renal Impairment or Abnormal Hepatic Function**.

Morphine should be administered with caution and in reduced dosages to elderly or debilitated patients. Respiratory depression occurs more frequently in these patients. The pharmacodynamics of morphine are more variable in geriatric patients than in younger adults. Therefore, initial dosage should be selected carefully based on clinical assessment of response to test doses and consideration of the patient's age and ability to clear the drug.

## Effect on Laboratory Tests

Morphine impairs gastric emptying, thereby invalidating test results in gastric emptying studies.

Morphine may interfere with hepatobiliary imaging using technetium Tc<sup>99m</sup> disofenin. Morphine may constrict the sphincter of Oddi and increase biliary tract pressure, preventing delivery of Tc<sup>99m</sup> disofenin to the small bowel. These actions result in delayed visualisation, and thus resemble biliary obstruction.

## 4.5 Interactions with other medicines and other forms of interaction

Acidifying agents generally increase the clearance of morphine, thus antagonising its effects, while alkalinising agents decrease clearance and so potentiate the effects of morphine.

**CNS Depressants:** Morphine should be used with great caution and in reduced dosage in patients concurrently receiving other CNS depressants including other opioid analgesics, benzodiazepines, gabapentinoids, cannabis, sedatives, hypnotics, tricyclic antidepressants, antipsychotics, antihistamines, centrally-active anti-emetics, general anaesthetics, tranquilisers, beta blockers or other CNS depressants, including alcohol because of the risk of respiratory depression, hypotension and profound sedation or coma. When such combined therapy is contemplated, the dose of one or both agents should be reduced. Patients should be cautioned accordingly.

<b>Benzodiazepines and other Central Nervous System (CNS) Depressants</b>	
<b>Clinical Impact</b>	Due to additive pharmacologic effect, the concomitant use of morphine with CNS depressant medicines increases the risk of respiratory depression, profound sedation, coma, and death.
<b>Intervention</b>	Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs

	of respiratory depression and sedation (see <b>section 4.4 Special warnings and precautions for use</b> ).
<b>Examples</b>	CNS depressant medicines, such as other opioid analgesics, benzodiazepines, gabapentinoids, cannabis, sedatives, hypnotics, tricyclic antidepressants, antipsychotics, antihistamines, centrally-active anti-emetics, general anaesthetics, tranquilisers, beta blockers and other CNS depressants, including alcohol.

Significant impairment of motor function has also been noted following concomitant morphine administration and alcohol ingestion.

Diazepam, when used following high doses of morphine, exacerbates the hypotensive effects produced by morphine, and is associated with decreased blood catecholamine levels.

**Antihypertensive Agents:** Concurrent administration of morphine may increase the hypotensive effects of antihypertensive agents or other drugs with hypotensive effects.

**Muscle Relaxants:** Morphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.

**Mixed Agonist/Antagonist Opioid Analgesics:** From a theoretical perspective, mixed agonist/antagonist opioid analgesics (e.g., pentazocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure opioid agonist analgesic. In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect or may precipitate withdrawal syndrome.

**Monoamine Oxidase Inhibitors (MAOIs):** MAOIs intensify the effects of morphine and other opioid drugs which can cause anxiety, confusional state, and significant respiratory depression, sometimes leading to coma. Morphine should not be given to patients taking MAOIs or within 14 days of stopping such treatment (see **section 4.3 Contraindications**). It is unknown whether there is an interaction between the new selective MAOIs (e.g., moclobemide and selegiline) and morphine. Therefore, caution is advised with such drug combinations.

**Cimetidine and Other H<sub>2</sub> Receptor Antagonists:** There is a report of confusional state and severe respiratory depression when a haemodialysis patient was administered morphine and cimetidine.

A potentially lethal interaction between cimetidine and morphine, in which the patient exhibited apnoea, a significantly reduced respiratory rate and suffered a generalised tonic-clonic seizure, has been reported. Administration of naloxone increased the respiratory rate; however, confusional state, disorientation, generalised muscle twitching and periods of apnoea persisted for 80 hours. Confusional state has also been associated with concomitant use of ranitidine and morphine.

**Diuretics:** Morphine reduces the efficacy of diuretics by inducing the release of antidiuretic hormone. Morphine may also lead to urinary retention by causing spasm of the sphincter of the bladder, particularly in men with prostatism.

**Phenothiazines:** The analgesic effect of morphine is potentiated by chlorpromazine.

**Amphetamines:** Dexamphetamine and other amphetamines may enhance the analgesic effects and decrease the sedation and depressed level of consciousness caused by morphine.

**Anticoagulants:** Morphine may potentiate the anticoagulant activity of coumarin anticoagulant agents.

**Metoclopramide and domperidone:** Morphine may antagonise the effects of metoclopramide and domperidone on gastrointestinal motility. Intravenous metoclopramide antagonises the effects of morphine on gastric emptying.

**Zidovudine:** Morphine may alter the metabolism of zidovudine, by competitively inhibiting glucuronidation or directly inhibiting hepatic microsomal metabolism. Zidovudine and morphine should therefore not be administered concurrently, because the toxicity of either or both of these drugs may be increased.

**Ritonavir:** Ritonavir may increase the activity of glucuronyl transferases and co-administration with morphine may result in decreased morphine serum levels and possible loss of analgesic efficacy.

**Oral Drugs:** Morphine impairs gastric emptying, so may affect the absorption of orally administered drugs. For example, morphine delays the absorption of paracetamol, mexiletine (anti-arrhythmic) and P2Y<sub>12</sub> inhibitors.

**Anticholinergic Agents:** Concurrent administration of morphine and anticholinergic agents (such as atropine) or other drugs with anticholinergic activity may increase the risk of constipation; this may lead to paralytic ileus and/or urinary retention.

**Antidiarrhoeal and antiperistaltic agents (such as loperamide and kaolin):** Concurrent administration of morphine and antidiarrhoeal agents with antiperistaltic actions may increase the risk of constipation and CNS depression.

**Opioid Antagonists:** Naloxone antagonises the analgesic, CNS and respiratory depressive effects of morphine, and may precipitate withdrawal in patients who are physically dependent on opioids.

Naltrexone blocks the therapeutic effects of opioids, so should be discontinued several days prior to elective surgery if administration prior to, during, or following surgery is unavoidable. Administration of naltrexone to a patient who is physically dependent on morphine will precipitate withdrawal syndrome.

### **P2Y<sub>12</sub> Inhibitors**

**Clinical Impact:** The co-administration of oral P2Y<sub>12</sub> inhibitors and morphine can decrease the absorption and peak concentration of oral P2Y<sub>12</sub> inhibitors and delay the onset of the antiplatelet effect, due to morphine's effect on gastric emptying (see **section 4.4 Special warnings and Precautions for Use**).

**Intervention:** Consider the use of a parenteral antiplatelet agent in the setting of acute coronary syndrome requiring co-administration of morphine.

Examples of P2Y<sub>12</sub> inhibitors include but are not limited to: clopidogrel, prasugrel, ticagrelor.

## **Serotonergic Drugs**

The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. Drugs that affect the serotonergic neurotransmitter system include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT<sub>3</sub> receptor antagonists and monoamine oxidase inhibitors (MAOIs).

## **Rifampicin**

Plasma concentrations of morphine may be reduced by rifampicin. The analgesic effect of morphine should be monitored and doses of morphine adjusted during and after treatment with rifampicin.

## **Antibacterials**

The opioid analgesic piperacetemol has been shown to reduce plasma ciprofloxacin concentration. The ciprofloxacin manufacturer advises that premedication with opioid analgesics be avoided.

## **4.6 Fertility, pregnancy and lactation**

### **Effects on Fertility**

Prolonged use of opioids may result in impairment of reproductive function, including fertility and sexual dysfunction in both sexes, and irregular menstruation in women.

### **Use in Pregnancy - Category C**

*Australian pregnancy categorisation (Category C): Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible.*

Morphine has been associated with fetal CNS defects in rodent studies. It is not known whether morphine can cause fetal harm in humans when administered during pregnancy. Pregnant patients should only be given morphine when the benefits clearly outweigh potential risks to the fetus.

Prolonged use of morphine during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognised and treated. Babies born to mothers who are physically dependent on morphine may also be physically dependent on the drug. If prolonged use is required in a pregnant woman, advise the patient of the risk of neonatal drug withdrawal syndrome and ensure that appropriate treatment will be available.

### **Use in Labour/Delivery**

Morphine is not recommended for use in women during and immediately before labour. The effects of opioid analgesics are unpredictable. They may prolong labour by temporarily reducing the strength, duration and frequency of uterine contractions, or conversely, they may tend to shorten labour by increasing the rate of cervical dilatation.

Morphine crosses the placenta and can produce respiratory depression in the neonate if it is administered during labour. Infants born to mothers receiving opioid analgesics during labour should be observed closely for signs of respiratory depression. In such infants, a specific opioid antagonist, naloxone hydrochloride, should be available for reversal of opioid-induced respiratory depression.

### **Use in Lactation**

Morphine is excreted in human milk and breast-feeding is not recommended while a patient is receiving morphine. Withdrawal syndrome has been observed in breast-fed infants when maternal administration of morphine is stopped.

## **4.7 Effects on ability to drive and use machines**

Occupational hazards: Morphine may cause somnolence and general impairment of co-ordination and may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a car or operating machinery. Morphine in combination with other opioid analgesics, phenothiazines, sedative-hypnotics and alcohol have additive depressant effects. Patients should be cautioned accordingly.

## **4.8 Undesirable effects**

The adverse reactions caused by morphine are essentially the same as those observed with other opioid analgesics. They include the following major hazards: respiratory depression, apnoea and to a lesser degree cardiovascular insufficiency, respiratory arrest, shock and cardiac arrest.

**Most Common Adverse Effects:** Constipation, dizziness, sedation, nausea, vomiting, hyperhidrosis, dysphoria and euphoric mood. Drug tolerance generally develops with long-term use, but not to constipation.

**Sedation:** Most patients receiving morphine will experience initial somnolence. This usually disappears in three to five days and is not a cause for concern unless it is excessive or accompanied with balance disorder or confusional state. Excessive or persistent sedation should be investigated. Factors to be considered should include concurrent sedative medications, the presence of hepatic or renal failure, exacerbated respiratory failure, drug tolerance to the dose used, especially in older patients, disease severity and the patient's general condition. If the dose of morphine has been reduced and pain is not adequately controlled, the dose may be carefully increased again after a few days.

Dizziness and balance disorder may be associated with morphine-induced orthostatic hypotension particularly in elderly or debilitated patients. The dosage should be adjusted according to individual needs but, because of reduced clearance, dosage may be lower in patients over 50 years of age.

**Nausea and Vomiting:** Nausea and vomiting are common after single doses of morphine or as an early undesirable effect of regular opioid therapy. The prescription of a suitable anti-emetic should be considered. The frequency of nausea and vomiting usually decreases within a week or so but may persist due to opioid-induced gastric emptying. Metoclopramide is often useful in such patients.

**Constipation:** Virtually all patients suffer from constipation while taking opioids on a chronic basis. Some patients, particularly elderly, debilitated or bedridden patients, may become impacted. Patients must be cautioned accordingly, and laxatives, softeners and other appropriate treatments should be initiated at the beginning of opioid therapy.

**Other Adverse Reactions Include:**

**Vascular Disorder:** Flushing, hypotension, hypertension.

**Cardiac Disorders:** Tachycardia, bradycardia, palpitations.

**Nervous System Disorders:** Headache, tremor, myoclonus, dizziness, syncope, nystagmus, allodynia hyperaesthesia, taste disorder.

**Gastrointestinal Disorders:** Dry mouth, constipation, gastrointestinal pain, abdominal pain, biliary tract pain, biliary colic and pancreatitis.

**Hepatobiliary Disorders:** Spasm of sphincter of Oddi.

**Respiratory, Thoracic and Mediastinal disorders:** Laryngospasm.

**Renal and Urinary Disorders:** Urinary retention or hesitation, ureteric spasm. Tolerance develops to the effects of opioids on the bladder.

**Reproductive System and Breast Disorders:** Erectile dysfunction, amenorrhoea.

**Endocrine Disorders:** A syndrome of inappropriate antidiuretic hormone secretion characterised by hyponatraemia secondary to decreased free-water excretion may occur (monitoring of electrolytes may be necessary). Morphine stimulates prolactin release and may also cause hyperglycaemia. Hypogonadism.

**Ear and labyrinth Disorders:** Vertigo.

**Eye Disorders:** Blurred vision, diplopia, miosis.

**Nutritional and metabolic disorders:** Decreased appetite.

**Skin and Subcutaneous Tissue Disorders:** Acute generalised exanthematous pustulosis (AGEP), pruritus, urticaria, other rashes including contact dermatitis.

**Immune System Disorders:** Hypersensitivity may be due to histamine release and may be more frequent in asthmatic patients. Anaphylactic reactions following intravenous injection have been reported rarely.

**Psychiatric Disorders:** Restlessness, anxiety, agitation, irritability, decreased libido, insomnia, delirium, confusional state and occasionally hallucination, altered mood including euphoric moods and dysphoria. The euphoric activity of morphine has led to its abuse.

**General disorders and administration site conditions:** Chills, asthenia, oedema. Injection site pain, local tissue irritation and induration following subcutaneous injection, particularly when repeated.

**Dependence/Drug Tolerance:** Physical and/or psychological dependence and drug tolerance may develop with long-term use of morphine. In drug dependence, “drug craving” is often involved. Repeated use of morphine can lead to drug dependence, even at therapeutic doses. The risk of drug dependence may vary depending on a patient’s individual risk factors, dosage, and duration of opioid treatment (see **section 4.4 Special warnings and precautions for use**).

**Drug Withdrawal Syndrome:** Chronic use of opioid analgesics may be associated with the development of physical dependence, with or without psychological dependence. Drug withdrawal syndrome may be precipitated when opioid administration is suddenly discontinued, or opioid antagonists administered.

Withdrawal syndrome symptoms that may be observed after discontinuation of opioid use include pain, diarrhoea, piloerection, decreased appetite, nervousness or restlessness, rhinorrhoea, sneezing, tremors or chills, restless legs syndrome, abdominal pain, nausea, influenza like illness, sleep disorder, unusual hyperhidrosis and yawning, asthenia, tachycardia, mydriasis and pyrexia. With appropriate dose adjustments and gradual withdrawal these symptoms are usually mild.

### **Reporting of Suspected Adverse Reactions**

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions <https://pophealth.my.site.com/carmreportnz/s/>.

## **4.9 Overdose**

### **Symptoms**

Overdosage with morphine is characterised by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), pneumonia aspiration, pulmonary oedema, somnolence progressing to stupor or coma, confusional state, dizziness, severe nervousness or restlessness, hallucinations, seizures (especially in infants and children), skeletal muscle hypotonia, hypothermia, cold sweat and sometimes bradycardia and hypotension. Rhabdomyolysis, progressing to renal failure, has been reported in overdosage. In severe overdosage, apnoea, circulatory collapse, cardiac arrest and death may occur.

The triad of respiratory depression, coma and miosis is considered indicative of opioid overdosage with mydriasis occurring as hypoxia develops. Death may occur from respiratory failure.

### **Treatment**

Immediate attention should be given to the re-establishment of adequate respiratory exchange through provision of a patent airway and institution of assisted or controlled ventilation.

In patients physically dependent on opioids, respiratory support is the first line of treatment. In these patients, the use of naloxone is potentially dangerous.

Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated.

The opioid antagonist, naloxone, is a specific antidote against respiratory depression which may result from overdosage or unusual sensitivity to opioids. The recommended adult dose of naloxone for the treatment of severe opiate-induced respiratory depression is 0.4 to 2 mg intravenously every 2 to 3 minutes as necessary, simultaneously with assisted respiration.

For children, the initial dose recommended is 0.01 mg/kg naloxone. A response should be seen after 2 to 3 doses. Note the duration of action of naloxone is usually shorter than that of morphine and thus the patient should be carefully observed for signs of depressed level of consciousness returning.

If the response to naloxone is suboptimal or not sustained, additional naloxone may be administered as needed, or given by continuous intravenous infusion to maintain alertness and respiratory function. There is no information available about the cumulative dose of naloxone that may be safely administered.

Naloxone should not be administered in the absence of clinically-significant respiratory or cardiovascular insufficiency secondary to morphine overdosage.

Naloxone should be administered cautiously to persons who are known or suspected to be physically dependent on morphine. In such cases, an abrupt or complete reversal of opioid effects may precipitate an acute withdrawal syndrome. The severity of the withdrawal syndrome produced will depend on the degree of physical dependence and the dose of the antagonist administered. If it is necessary to treat serious respiratory depression in the physically dependent patient, the antagonist should be administered with extreme care and by titration with smaller than usual doses of the antagonist.

Morphine toxicity may be a result of overdosage but because of the large inter-individual variation in sensitivity to opioids, it is difficult to assess the exact dose of any opioid that is toxic or lethal. The toxic effects of morphine tend to be overshadowed by the presence of pain or drug tolerance. Patients having chronic morphine therapy have been known to take in excess of 3,000 mg/day with no apparent toxic effects being present.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

## **5. PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

Morphine is the principal alkaloid of opium. Morphine acts as an agonist, binding to receptors in the brain, spinal cord and other tissues. These sites have been classified as *mu* receptors and are widely distributed throughout the central nervous system being present in highest concentration in the limbic system.

Morphine exerts its primary effects in the central nervous system and organs containing smooth muscle.

Morphine produces many effects, including analgesic therapy, gastrointestinal motility disorder, respiratory depression, somnolence, altered mood and alterations of the endocrine and autonomic nervous systems.

Nausea and vomiting may occur through direct stimulation of the chemoreceptor trigger zone (CTZ).

Urinary retention may occur due to increased bladder sphincter tone.

## **5.2 Pharmacokinetic properties**

### **Absorption**

Absorption of morphine sulfate pentahydrate after intramuscular and subcutaneous injection is fairly rapid with peak analgesic therapy occurring 30 to 60 minutes and 50 to 90 minutes after injection via the respective routes. Peak analgesic therapy occurs within 20 minutes after intravenous administration.

### **Distribution**

Morphine is distributed throughout the body, but particularly to parenchymatous tissue such as kidney, lung, liver and spleen. Lower concentrations are found in skeletal muscle and brain tissue. Morphine diffuses across the placenta and trace amounts are found in sweat and breast milk. About 35% is protein bound, mainly to albumin.

### **Metabolism**

Morphine is metabolised principally in the liver by conjugation with glucuronic acid. The principal metabolites are morphine-3-glucuronide and morphine-6-glucuronide. Morphine-6-glucuronide is pharmacologically active and has a half-life somewhat longer than morphine.

### **Elimination**

Elimination half-life from serum is approximately 1.5 to 2 hours in healthy subjects and 90% of the dose is recovered in urine within 24 hours. Approximately 7 to 10% of the dose is recovered in faeces, the majority after conjugation and excretion via bile.

Chinese subjects given intravenous morphine have a higher rate of clearance when compared to white subjects ( $1852 \pm 116$  mL/min versus  $1495 \pm 80$  mL/min) because of an increase in the partial metabolic clearance by glucuronidation.

### **Children**

See **section 4.4 Special warnings and precautions for use – Paediatric Use** and **section 4.2 Dose and method of administration**.

### **Elderly**

In older patients, the volume of distribution is considerably smaller and initial concentrations of morphine are correspondingly higher. See also **section 4.4 Special warnings and precautions for use – Other Special Risk Patients and Elderly Patients**.

## Disease States

See section 4.4 Special warnings and precautions for use – Renal Impairment or Abnormal Hepatic Function.

## 5.3 Preclinical safety data

The carcinogenic or mutagenic potential of morphine has not been established.

## 6. PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Sodium chloride

Water for injections

1N hydrochloric acid (for pH adjustment)

The solution does not contain any antioxidant or preservative.

### 6.2 Incompatibilities

A solution of thiopentone and morphine forms an inactive preparation.

### 6.3 Shelf life

The shelf life of unopened DBL Morphine Sulfate Injection ampoules is 24 months for the 5 mg/mL and 30 mg/mL presentations, and 30 months for the 10 mg/mL and 15 mg/mL presentations.

### 6.4 Special precautions for storage

Store at or below 25°C. Protect from light.

DBL Morphine Sulfate Injection should be used within 24 hours of opening, in order to avoid the risk of microbial contamination.

**Warning:** As with all parenteral drug products, intravenous admixtures should be visually inspected for clarity, particulate matter, precipitate and leakage prior to administration, whenever solution and container permit. Solutions showing haziness, particulate matter, precipitate or leakage should not be used. Development of a yellow colour in morphine solutions does not indicate toxicity or loss of potency or efficacy.

### 6.5 Nature and contents of container

#### Package Quantities

DBL Morphine Sulfate Injection ampoules are available as follows:

Strength	Pack Size(s)
5 mg/mL	5

10 mg/mL	5 and 50
15 mg/mL	5 and 50
30 mg/mL	5 and 50

Not all pack sizes may be marketed.

## 6.6 Special precautions for disposal

Contains no antimicrobial agent. Product is for single use in one patient only. Discard any residue.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

## 7. MEDICINE SCHEDULE

Class B1 Controlled Drug

## 8. SPONSOR

Pfizer New Zealand Limited  
PO Box 3998  
Auckland, New Zealand

Toll Free Number: 0800 736 363  
www.pfizermedicalinformation.co.nz

## 9. DATE OF FIRST APPROVAL

28 April 1983

## 10. DATE OF REVISION OF THE TEXT

10 November 2023

™ = Trademark

## Summary Table of Changes

Section changed	Summary of new information
Throughout	Minor editorial changes and MedDRA terminology updates
4.2	Add advisory information relating to treatment goals and discontinuation, and duration of treatment.
4.4	Add precautionary information relating to: <ul style="list-style-type: none"> <li>• drug use disorder.</li> <li>• risk of biliary tract symptoms and pancreatitis.</li> </ul>

Section changed	Summary of new information
	<ul style="list-style-type: none"> <li>• concomitant use of morphine and oral P2Y<sub>12</sub> inhibitor antiplatelet therapy.</li> <li>• acute generalised exanthematous pustulosis (AGEP).</li> </ul>
4.5	P2Y <sub>12</sub> inhibitors: Add cross-reference to section 4.4.
4.8	<ul style="list-style-type: none"> <li>• Add additional adverse effects: pancreatitis, spasm of sphincter of Oddi, acute generalised exanthematous pustulosis (AGEP).</li> <li>• Add more information about dependence/tolerance and add cross-reference to section 4.4.</li> </ul>
8	Add Sponsor's website address.